You are here

CD34+ Stem Cell Therapy for Refractory Angina`

Patients with refractory angina who are suboptimal candidates for further revascularization display improved exercise time, decreased angina frequency, and reduced major adverse cardiac events following the intramyocardial delivery of CD34+ stem cells; however, the effect of CD34+ stem cell therapy on health care expenditures after treatment remains unclear. In a new STEM CELLS Translational Medicine article, researchers led by Jay H. Traverse (University of Minnesota School of Medicine, Minneapolis, Minnesota, USA) report on their determination of the effect of CD34+ stem cell therapy on cardiac‐related hospital visits and costs during the 12 months following stem cell injection compared with the 12 months before injection. Overall, Johnson et al. provide evidence that CD34+ stem cell therapy for patients with refractory angina associates with improved mortality, a reduction in hospital visits, and lower expenditures for cardiac procedures in the year following treatment.